At a glance
ClinicalIndex Comparison Record- ✓African American ancestry (including those born in Caribbean, Africa, Canada, etc.)
- ✓Untreated hypertension with average sitting BP 140/90–159/99 mmHg, OR controlled BP (<140/90) or stage 1 hypertension (<160/100) on 1-2 antihypertensives (but not beta-blockers or calcium channel blockers for cardiovascular indications)
- ✓Spot urine protein/creatinine ratio <0.5 (≈500 mg/day urinary protein)
- ✓eGFR ≥60 mL/min/1.73 m² by MDRD equation
- ✕History of malignant or accelerated hypertension
- ✕WBC <2,500/mm³, anemia, or thrombocytopenia
- ✕Known liver disease
- ✕Known secondary cause of hypertension
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Uric Acid and Hypertension in African Americans
In Brief
A Phase 3 clinical trial evaluating Allopurinol, Placebo, and 2 other interventions for Cardiovascular Diseases and 2 related conditions. Completed, enrolled 150 participants across 1 site.
Detailed Summary
This study will test the hypothesis that the administration of a xanthine oxidase inhibitor (allopurinol) will prevent thiazide-induced hyperuricemia, which will result in better blood pressure (BP) control in African Americans.
Study Details
Timeline
Interventions
Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.